Biography for Emily Mullin
Emily Mullin, Associate Editor
Before joining the Fierce life sciences team as an associate editor, Emily Mullin was a reporter at the Baltimore Business Journal, where she covered the healthcare and biotechnology industries, and a staff writer for Dorland Health, a healthcare trade publishing company based in Rockville, MD. She has served as a contributing writer to The Maryland Daily Record, where she’s covered topics ranging from neuroscience to hospital consolidation. Her business and healthcare stories have also appeared in Nephrology Times, Columbus Business First and the Cincinnati Business Courier. She is based in Washington, DC, and is a graduate of the E.W. Scripps School of Journalism at Ohio University. You can contact her at firstname.lastname@example.org and follow her on Twitter at @EmilyMFierce.
- Contact Emily
- Follow Emily on Google+
Articles by Emily Mullin
In an important step toward the creation of a vaccine against deadly coronaviruses, researchers from Purdue University have figured out how to disable a key enzyme of the SARS virus that helps it hide from the immune system.
The Scripps Research Institute has landed a $13 million grant from the National Institute of Allergy and Infectious Diseases to advance antibodies toward the development of an HIV vaccine. Meanwhile, another team of researchers at the University of Nebraska-Lincoln has won nearly $2 million for its experimental HIV vaccine.
Two doses of the oral cholera vaccine Shanchol provided an 86% percent protection rate during a recent outbreak in Guinea, according to a new study.
A new analysis published in the Canadian Medical Association Journal shows that vaccination rates among healthcare workers in Canada are less than 50%, well below the level necessary for herd immunity.
The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.
Virulent flu strains pose the danger of potential release, even when used in experiments for vaccine research, and investigators from the Harvard and Yale universities are calling for greater scrutiny of such studies.
BOSTON--Sanofi's Phase II trial results for its Clostridium difficile vaccine are proof that the French drug giant is leading the race for preventive therapies for the deadly bacterial infection.
Software developed by researchers at the University of Pittsburgh and Johns Hopkins University has helped the Republic of Benin in West Africa deliver more vaccines to children most in need, according to a new study.
Not enough people are being vaccinated against shingles, and those who are at the highest risk for the painful viral infection, such as those with immunosuppressive disorders like HIV, are not able to receive the vaccine because of safety issues, according to a new study.
In light of news that polio has once again emerged as a public health emergency, vaccinemakers GlaxoSmithKline and Sanofi are reportedly on watch.